Romiplostim for the treatment of chronic immune thrombocytopenia

Technology appraisal guidance
Reference number: TA221
Published: 27 April 2011
Last updated: 26 October 2018

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from Amgen

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from Amgen

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from Amgen
17 March 2011
(166.63 Kb 48 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 15 March 2011